Ain Shams University, Cairo, Egypt and Dr Erfan and Bagedo General Hospital, King Fahad St. (Al Sitteen), PO Box 6519, Jeddah 21452, Saudi Arabia.
Curr Med Res Opin. 2010 Feb;26(2):337-43. doi: 10.1185/03007990903471940.
To determine the prevalence of painful diabetic peripheral neuropathy in adult patients with diabetes mellitus (type 1 and 2) attending outpatient clinics in Saudi Arabia and to determine the demographic profile and pharmaceutical management of these patients.
Eligible patients from 100 outpatient clinics treating patients with diabetes mellitus across Saudi Arabia completed an epidemiologic questionnaire to obtain demographic information and medication history. Following this, the validated DN4 pain questionnaire was used to identify the presence of painful diabetic peripheral neuropathy (score of > or =4).
A total of 1039 patients were enrolled. Following the DN4 pain questionnaire, an overall prevalence of painful diabetic peripheral neuropathy of 65.3% (n = 678) was found. The age of patients, their sex, and the duration of underlying diabetes were found to be statistically significant factors in the development of painful diabetic peripheral neuropathy. No statistically significant difference was found between smoking history, body mass index, or racial origin and presence of painful diabetic peripheral neuropathy. On initial evaluation, 42.3% (n = 440) stated they were receiving treatment for pain. Following evaluation using the DN4 pain questionnaire, the number prescribed therapeutic pain management increased to more than two thirds (68.7%, n = 714) of which 62.3% (n = 579) were prescribed pregabalin.
In patients with reduced pain intensity DN4 has not been directly compared with other tools to measure neuropathic pain; however, using the DN4 in this study 65.3% of adult outpatients with type 1 and 2 diabetes in Saudi Arabia were found to have painful diabetic peripheral neuropathy; far higher than anticipated.
确定在沙特阿拉伯接受门诊治疗的成年 1 型和 2 型糖尿病患者中疼痛性糖尿病周围神经病变的流行情况，并确定这些患者的人口统计学特征和药物治疗管理情况。
沙特阿拉伯各地 100 家治疗糖尿病患者的门诊诊所中，符合条件的患者完成了一份流行病学调查问卷，以获取人口统计学信息和药物治疗史。之后，使用经过验证的 DN4 疼痛问卷来确定是否存在疼痛性糖尿病周围神经病变（评分>或=4）。
共纳入 1039 例患者。根据 DN4 疼痛问卷，发现疼痛性糖尿病周围神经病变的总体患病率为 65.3%（n=678）。患者年龄、性别和基础糖尿病病程均为疼痛性糖尿病周围神经病变发生的统计学显著相关因素。吸烟史、体重指数或种族与疼痛性糖尿病周围神经病变之间未发现统计学显著差异。在初始评估时，42.3%（n=440）的患者表示正在接受疼痛治疗。根据 DN4 疼痛问卷评估后，开具治疗性疼痛管理药物的患者比例增加到三分之二以上（68.7%，n=714），其中 62.3%（n=579）的患者开具了普瑞巴林。
在疼痛强度降低的患者中，DN4 并未与其他用于测量神经病理性疼痛的工具直接比较；然而，在本研究中使用 DN4 发现，沙特阿拉伯接受门诊治疗的 1 型和 2 型成年糖尿病患者中，有 65.3%患有疼痛性糖尿病周围神经病变；远高于预期。
